A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Saved in:

Bibliographic Details
Title:	A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
Authors:	Eda, H¹, Santo, L¹, Cirstea, D D¹, Yee, A J¹, Scullen, T A¹, Nemani, N¹, Mishima, Y¹, Waterman, P R², Arastu-Kapur, S³, Evans, E⁴, Singh, J⁴, Kirk, C J³, Westlin, W F⁴, Raje, N S¹
Source:	Leukemia (08876924). Sep2014, Vol. 28 Issue 9, p1892-1901. 10p. 6 Graphs.
Database:	Academic Search Ultimate

Description
ISSN:	08876924
DOI:	10.1038/leu.2014.69